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Abstract
Hepatitis C virus infection induces inflammation and while it is believed that HIV co-infection
enhances this response, HIV control may reduce inflammation and liver fibrosis in resolved
or viremic HCV infection. Measurement of systemic biomarkers in co-infection could help
define the mechanism of inflammation on fibrosis and determine if HIV control reduces liver
pathology. A nested case-control study was performed to explore the relationship of sys-
temic biomarkers of inflammation with liver fibrosis in HCV viremic and/or seropositive
women with and without HIV infection. Serum cytokines, chemokines, growth factors and
cell adhesion molecules were measured in HIV uninfected (HIV-, n = 18), ART-treated HIV-
controlled (ARTc, n = 20), uncontrolled on anti-retroviral therapy (ARTuc, n = 21) and elite
HIV controllers (Elite, n = 20). All were HCV seroreactive and had either resolved (HCV
RNA-; <50IU/mL) or had chronic HCV infection (HCV RNA+). In HCV and HIV groups,
aspartate aminotransferase to platelet ratio (APRI) was measured and compared to serum
cytokines, chemokines, growth factors and cell adhesion molecules. APRI correlated with
sVCAM, sICAM, IL-10, and IP-10 levels and inversely correlated with EGF, IL-17, TGF-α
and MMP-9 levels. Collectively, all HCV RNA+ subjects had higher sVCAM, sICAM and IP-
10 compared to HCV RNA-. In the ART-treated HCV RNA+ groups, TNF-α, GRO, IP-10,
MCP-1 and MDC were higher than HIV-, Elite or both. In ARTuc, FGF-2, MPO, soluble E-
selectin, MMP-9, IL-17, GM-CSF and TGF-α are lower than HIV-, Elite or both. Differential







Citation: Keating SM, Dodge JL, Norris PJ,
Heitman J, Gange SJ, French AL, et al. (2017) The
effect of HIV infection and HCV viremia on
inflammatory mediators and hepatic injury—The
Women’s Interagency HIV Study. PLoS ONE 12(9):
e0181004. https://doi.org/10.1371/journal.
pone.0181004
Editor: Jason Blackard, University of Cincinnati
College of Medicine, UNITED STATES
Received: February 8, 2017
Accepted: May 22, 2017
Published: September 13, 2017
Copyright: © 2017 Keating et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Data are from the
Women’s Interagency HIV Study (WIHS), whose
authors may be contacted at JHSPH.wdmac@jhu.
edu. Data are available to all investigators in two
ways. The WIHS Public Data Set provides de-
identified data (meeting HIPAA criteria) that may
assist anyone interested in public health research.
Access to the WIHS Public Data Set may be
obtained by filling out the WIHS Public Use Data
Set Request form at wihshealth.org. Data are
updated annually. Alternatively, the WIHS
expression of soluble markers may reveal mechanisms of pathogenesis or possibly reduc-
tion of fibrosis in HCV/HIV co-infection.
Introduction
Hepatic disease is a leading cause of significant morbidity and death among HIV infected per-
sons in the US; 15–30% of HIV-infected individuals are coinfected with hepatitis C virus
(HCV)[1–4] and this is associated with metabolic and cardiovascular complications in addi-
tion to other inflammation induced comorbidities. Individually, HIV and HCV infections
increase expression of inflammatory cytokines and chemokines [5–7]. These factors have been
found to be associated with long-term morbidity in HIV infection or chronic hepatitis [7–11].
Additionally, HIV infection with HCV viral hepatitis more than triples the rate of liver disease,
liver failure, and liver-related death [1]. The mechanisms causing accelerated disease with co-
infection are not well understood but there is evidence that HIV infection increases morbidity
in HCV co-infected individuals [12]. HIV-induced immune perturbation, including CD4 cell
loss, generalized inflammation and trafficking of activated immune cells to the liver in HCV
infection likely also results in greater tissue damage and fibrosis [13,14].
Although an HIV-specific host immune response is required to control HIV viremia, it
may also result in broad and non-specific immune activation and an array of tissue injuries
including hepatic fibrosis. Alternatively, HIV suppression may reduce non-specific inflamma-
tion and reduce bystander inflammation-induced fibrosis. Individually, HIV and HCV
immune activation induces expression of inflammatory cytokines (e.g. TNF-α and IL-1β
[15,16]) and chemokines (IP-10, MCP-1, MIG and ITAC [13,17–20]) directing cellular
immune responses to sites of infection. Enhanced expression of chemokine receptors on lym-
phocytes (e.g. CXCR3 [21–24]) increases the transit of immune cells to sites of infection;
meanwhile, higher expression of cellular adhesion molecules increases cell trafficking through
the vascular endothelium to the site of infection [18,25–27].
In order to further investigate the effect of different states of HIV infection on hepatic
injury in chronic HCV, we measured soluble biomarkers in HIV- and HIV+ women with
HCV. We hypothesized that lower inflammatory responses and less liver fibrosis would be
found in HCV+ women with controlled HIV replication including elite controllers and ART-
treated with viral suppression (ARTc) than in ART-treated women with uncontrolled HIV
replication (ARTuc). This would describe a distinct biomarker profile in relation to stage of
liver diseases and elucidate the clinically relevant biomarkers, and mechanisms of hepatic
pathogenesis in HIV/HCV co-infection.
Materials and methods
HCV antibody positive women
This study was limited to HCV serologically reactive women enrolled in the Women’s Inter-
agency HIV Study (WIHS). The details of this prospective, multi-center, longitudinal cohort
NIH study have been published previously [28]. Briefly, the WIHS enrolled 3766 adult women
in two recruitment periods (1994–1995 and 2001–2002) at six clinical sites across the United
States. Women were either infected with HIV or at high risk for acquiring the infection. Over-
all, 32% of HIV-seropositive and HIV-seronegative women had HCV antibody at enrollment.
All participants gave written, informed consent for the WIHS as approved by all Institutional
Review Boards (IRB) of the participating institutions and this study was approved by UCSF
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welcomes collaborations with investigators and
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IRB. Every 6 months, participants undergo a comprehensive physical examination, provide
biological specimens for CD4 cell count and HIV-RNA viral load determination, and complete
an interviewer-administered questionnaire that collects information on demographics, health
history, alcohol consumption and medication use. Heavy alcohol was defined as 14 or more
standard drinks per week.
Serologic reactivity to HCV was determined using a second-generation or third-generation
enzyme immunoassay (EIA, Ortho-Diagnostic Systems); women with positive EIA tests also
were assessed for HCV-RNA by RT-PCR (COBAS Amplicor HCV Detection Kit, Roche Diag-
nostic Systems). HIV-RNA was measured using the isothermal nucleic acid sequence-based
amplification (NASBA/Nuclisens) method (bioMerieux) with a detection limit of 80 copies/
mL. All women were hepatitis B surface Ag negative.
The study population was comprised of homogenous, well characterized HIV phenotypes
(stable for at least 1.5 years) stratified by serum HCV RNA positive (HCV RNA+) or negative
(HCV RNA-<50IU/mL). Women were matched by age, race/ethnicity, and HCV RNA status
within the following groups: Elite controllers (EC) were defined as ART-naïve, CD4 cell count
never below 500, HIV RNA < 80 copies /mL. Groups were limited to the number of EC
women within the WIHS where there were samples were available to study. These were very
carefully selected groups based on the number of Elite controllers. ART treated individuals
with controlled infection (ARTc) were HIV women currently on potent ART with viral con-
trol, with CD4 cell count > 350 cells/ml, HIV RNA< 80 copies/ml. ART treated with uncon-
trolled infection (ARTuc) were ART-treated women but without HIV uncontrolled having
HIV RNA80 copies/ml. HIV uninfected were HIV negative by EIA. No participants in this
study were HBV positive.
Assessment of liver fibrosis
The serum marker of liver fibrosis were aspartate aminotransferase (AST) to peripheral blood
platelet count ratio (APRI) [29] and FIB-4, both of which have been validated in HIV-HCV
coinfected women [30]. Using a laboratory upper limit of normal AST of 40 U/l, severe fibrosis
is defined by APRI >1.5, FIB-4 >3.25 and mild/no fibrosis as APRI score <0.5 and FIB-4
<1.5 [31].
Measurement of soluble immunologic markers
Plasma samples were assayed using a high-sensitivity Milliplex kit (Millipore) with antibody-
coated beads for detection of GM-CSF, interferon (IFN)-γ, interleukin(IL)-10, IL-12(p70), IL-
13, IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)- α;a standard-sensi-
tivity Milliplex Map kit (Millipore) for epidermal growth factor (EGF), eotaxin, fibroblast
growth factor (FGF)-2, fractalkine, Flt-3 ligand, GRO, G-CSF, IFN-α2, IL-1 α, IL-1Rα, IL-3,
IL-9, IL-12(p40), IL-15, IL-17, IFN-γ-induced protein (IP)-10, monocyte chemotactic protein
(MCP)-1, MCP-3, macrophage-derived chemokine (MDC), macrophage inflammatory pro-
tein (MIP)-1α, MIP-1 β, sIL-2 receptor α (Rα), transforming growth factor (TGF)- α, TNF- β,
vascular endothelial growth factor (VEGF) and soluble CD40 ligand (sCD40L) and a cardio-
vascular panel including soluble E-selectin, soluble vascular cell adhesion molecule (s-VCAM),
soluble intracellular adhesion molecule (s-ICAM), matrix metalloproteinase-9 (MMP-9), mye-
loperoxidase (MPO), total plasminogen activator inhibitor (tPAI). Testing was performed fol-
lowing the manufacturer’s protocols. Standard curves and samples were tested in duplicate.
The standard curve detection ranged from 2–25000 ng/mL for the cardiovascular panel, 1.3–
2000 pg/mL for the high sensitivity panel, and 3.2–10,000 pg/mL for the standard sensitivity
panel. The values that were out of range low were assigned a value half the lowest standard.
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The values that were out of range high were assigned a value twice the highest value in the set.
Results were acquired on a Labscan 200 analyzer (Luminex) using Bio-Plex manager software
v6.1 (Bio-Rad), and study plates were compiled using Data Pro (Bio-Rad). Data were exported
to Prism (Graphpad) for graphing and SAS for analysis.
Statistical analysis
Demographic and clinical characteristics were described with means (standard deviations),
medians (interquartile ranges) and frequencies (percent) stratified by HIV clinical subgroups
and presence or absence of HCV viremia. APRI, chemokines, 45 cytokines and cell adhesion
molecules were measured. Twelve soluble markers received 50% or fewer detectable results for
a given cytokine were excluded from further analysis; these included IL-4, IL-12p70, IL-13,
IFNα2, IL-1α, IL-1ra, IL-3, IL-9, IL-12-p40, IL-15, IL-2R α and TNF- β. One marker, soluble
CD40L, was out of range high in more than 50% of the results and was excluded from further
analysis. Cytokines compared by HCV viremia status using the t test and by HIV clinical sub-
groups using the Tukey method to account for multiple pairwise comparisons. Variables were
transformed (log10 or square root) to achieve normality, as needed. Correlation of CD4 count,
chemokines, cytokines and cell adhesion molecules with APRI were measured with Spear-
man’s rank correlation coefficients for the total population and within HCV RNA+ HIV clini-
cal subgroups. Given the small sample size within subgroups, non-parametric correlations
were used to minimize the influence of potential outliers. To control for the expected propor-
tion of incorrectly rejected null hypotheses, p-values for comparisons among biological mark-
ers were adjusted into FDR (False Discovery Rates) by the Benjamini and Hochberg
controlling procedure [32], a commonly used method for analysis of large sets of biological
data. While statistical significance was defined as p<0.05 and reported for all comparisons,
due to the small sample size and discovery nature of this study, the FDR are also reported to
describe the strength of the findings. Data analysis and graphing were performed by SAS ver-
sion 9.3 (Cary, NC) and Prism (GraphPad), respectively.
Results
Patient population
Seventy-nine HCV antibody positive women were identified and grouped as follows (Table 1):
Elites (n = 20), controlled HIV on ART (ARTc; n = 20); uncontrolled on ART (ARTuc; n = 21)
and HIV uninfected (n = 18). Mean age (SD) was 49 (±7) years ranging from 35.6–62.9 years,
mean CD4 cell count among HIV infected women was 681 cells/μL (±399), and 54% of
women reported being African American (AA). There were no differences in age and race
between the subgroups. To control for variations in all biomarkers for effects of alcohol con-
sumption, we compared the high (n = 20) and low alcohol consumers and found that there
were no differences in the biomarkers by alcohol consumption (p>0.05 for all cytokines).
There were 9 individuals who had received HCV treatment in the past and all failed to clear
HCV. All individuals who cleared HCV did so spontaneously, without treatment, prior to
entering WIHS.
Correlation of chemokines, cytokines and cell adhesion molecules levels
with liver fibrosis as measured by APRI
In another study based on a similar sample set in WIHS [14], it has been previously published
that APRI was higher in HCV RNA+ women compared to HCV RNA-. Furthermore, this pat-
tern of lower APRI in HCV non-viremic and higher APRI in HCV viremic women was
HIV/ HCV co-infection and liver fibrosis
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observed within each HIV clinical group. In Elite, APRI was higher in HCV RNA+ compared
to RNA-. APRI was also higher in HCV RNA+ compared to HCV RNA- subjects within each
of the other clinical groups (ARTc, ARTuc and HIV-). To identify soluble biomarkers and
inflammatory responses involved in hepatic injury, we focused our investigations on 32 mark-
ers including cytokines, chemokines and cell adhesion molecules (45 markers were measured,
32 markers were detectable; Table 2). We found that sVCAM (r = 0.38; p<0.001;
FDR = 0.008), sICAM (r = 0.32; p = 0.004; FDR = 0.03). IL-10 (r = 0.29; p = 0.01, FDR = 0.07)
and IP-10 (r = 0.45; p<0.001; FDR = 0.002) were positively correlated with APRI while IL-17
(r = -0.3; p = 0.007; FDR = 0.05), EGF (r = -0.25; p = 0.02; FDR = 0.13), TGF- α (r = -0.37;
p<0.001; FDR = 0.009) and MMP-9 levels (r = -0.41; p<0.001; FDR = 0.002) were inversely
correlated with the APRI (Fig 1). We found similar results with FIB-4 (S1 Fig). When stratify-
ing the HCV RNA+ group by HIV clinical subgroups, sVCAM levels correlated with APRI in
ARTuc (r = 0.66, p = 0.03; FDR = 0.3), while correlation of sICAM with APRI was found only
in the ARTc group (r = 0.72, p = 0.02; FDR = 0.2). None of the soluble markers correlated with
APRI in the elite controller group.
Soluble cytokines, chemokines and cell adhesion molecules are
associated with HCV viremia
Previous studies demonstrated that inflammatory liver diseases increase cell adhesion mole-
cules, chemokine and cytokine expression [13,23]. In HCV mono-infection viremia increases
cell adhesion molecules and chemokines directing cellular immune responses to the liver [33].
We found that HCV RNA+ status alone was associated with higher sVCAM (p = 0.01;
FDR = 0.15), sICAM (p = 0.004; FDR = 0.1) and IP-10 levels (p = 0.001; FDR = 0.02) (Fig 2)
compared to HCV RNA- status. In the HIV positive and negative subgroups, HCV RNA+ IP-
10 levels were higher in ARTc, elite controller and HIV uninfected women compared to the
Table 1. Demographics.
HIVneg Elite ARTc ARTuc
HCV RNA Neg (n = 8) Pos (n = 10) Neg (n = 9) Pos (n = 11) Neg (n = 10) Pos (n = 10) Neg (n = 10) Pos (n = 11)
Age, years
(mean ±SD)
51.3 ±4.8 45.5 ±7.5 46.9 ±7.7 47.6 ±6.4 50.9 ±7.2 51.0 ±4.1 48.8 ±7.8 48.6 ±5.9
Race, AA
(% total)
50% 50% 33% 64% 60% 70% 50% 55%
HIV RNA; log10 copies/mL
(mean ±SD)
ND ND ND ND 3.61 ±1.01 2.98 ±0.78
CD4 count*; cells/μL
(mean ±SD)
1123 ±336 910 ±254 897 ±255 918 ±429 996 ±336 722 ±226 297 ±171 294 ±169
HCV RNA; log10 copies/mL
(mean ±SD)
ND 5.49 ±1.06 ND 5.79 ±0.44 ND 6.14 ±0.93 ND 6.24 ±0.31
APRI 0.17 ±0.05 0.48 ±0.38 0.38 ±0.56 0.46 ±0.25 0.37 ±0.17 0.78 ±0.50 0.17 ±0.07 1.36 ±1.62
Serum AST log10
(mean ±SD)
1.22 ±0.11 1.55 ±0.21 1.27 ±0.10 1.53 ±0.14 1.46 ±0.15 1.64 ±0.18 1.19 ±0.08 1.68 ±0.27
Serum ALT; log10
(mean ±SD)




260.2 ±44.8 237.7 ±52.5 250.4 ±118.7 230.3 ±69.5 231.6 ±62.7 208.1 ±62.3 268.1 ±58.5 219.2 ±130.1
Abbreviations: SD = standard deviation; ND = not detectable (<80 RNA copies/mL for HIV and <80 RNA copies/mL for HCV); AA = African American.
*CD4 differed between HCV RNA negative versus positive (ARTc p = 0.04) and by HIV subgroup (ARTuc p<0.001).
https://doi.org/10.1371/journal.pone.0181004.t001
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Table 2. Biomarker measurements in all HCV and HIV groups.
HIV negative Elite RNA Neg ART Controlled ART Uncontrolled
HCV RNA Neg HCV RNA Pos HCV RNA Neg HCV RNA Pos HCV RNA Neg HCV RNA Pos HCV RNA Neg HCV RNA Pos

















IL-1α 0.3 (0.1–0.6) 2.6 (0.2–4.4) 0.1 (0.1–0.5) 0.3 (0.1–3.7) 0.1 (0.1–0.6) 0.3 (0.1–2.9) 0.3 (0.1–1) 0.1 (0.1–1)
IL-2 0.3 (0.1–1.5) 2.1 (0.2–7.9) 0.1 (0.1–0.8) 2.1 (0.2–5.9) 0.2 (0.1–0.4) 0.3 (0.2–1.7) 0.4 (0.1–1.1) 0.2 (0.1–0.9)
IL-5 0.3 (0.1–0.5) 0.4 (0.1–0.7) 0.2 (0.1–0.4) 0.4 (0.2–0.8) 0.4 (0.1–0.9) 0.4 (0.1–0.6) 0.4 (0.2–0.6) 0.2 (0.2–0.5)
IL-6 12.2 (5.5–22.2) 11.5 (7.4–23.4) 6.5 (2.7–21.6) 4.1 (2.7–23) 6.5 (1.5–13) 7.7 (1–13.7) 4.8 (3.7–10.1) 4.9 (2.3–6)
IL-7 4.5 (2.2–7.3) 8.4 (3.5–11.8) 5.7 (3.1–8.6) 3.5 (1.7–9.1) 10.5 (4.2–15.7) 7.7 (6.2–8.9) 15.3 (6.6–26.6) 11.1 (5.4–19.8)




18.7 (7.1–35.1) 22.1 (10.8–
55.6)
17.8 (6.9–42) 21.3 (14–67)
IL-10 6.5 (5.4–12.1) 27.2 (7.5–50.9) 8.9 (8–20.8) 14.1 (10.6–
34.9)






IFN-γ 0.1 (0.1–1.1) 1.1 (0.1–8.2) 1.4 (0.1–2) 1.5 (0.8–7.1) 0.1 (0.1–1.6) 0.3 (0.1–6.4) 0.1 (0.1–1.5) 0.1 (0.1–1)
Gm-CSF 0.4 (0.1–1.6) 3.8 (1.5–6) 0.3 (0.2–1) 0.5 (0.1–13.7) 0.2 (0.1–0.7) 1.2 (0.1–4.2) 0.1 (0.1–1.1) 0.1 (0.1–2.8)



































































































































18.2 (1.6–50.5) 44.9 (22.9–
70.3)
6.8 (1.6–31.7) 1.6 (1.6–79.1) 1.6 (1.6–63.6) 1.6 (1.6–111.9)
Fit-3
Ligand





1.6 (1.6–215.1) 33.8 (1.6–113) 1.6 (1.6–12.9) 67.1 (14.2–
161.5)
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corresponding HCV RNA- groups (Fig 3). Among ARTuc women, no difference in IP-10 by
HCV RNA status was detected (p = 0.34; FDR = 0.7) and IP-10 levels were significantly ele-
vated compared to HCV viremic ARTc, elite controller and HIV uninfected women.
Cytokine concentrations were compared among the HCV+ HIV negative and positive
groups. In HIV+ ART-treated groups, inflammatory cytokines and chemokines (TNF-α,
GRO, IP-10 and MDC) were higher compared to the other groups. Even in treated and sup-
pressed infection, chemokines MCP-1 and MDC were significantly elevated compared to the
other groups. Compared to ART-treated individuals, higher concentrations in the HIV nega-
tive or Elite were found in some soluble biomarkers including FGF-2, MPO, soluble E-selectin,
MMP-9, IL-17, GM-CSF and TGF-α(all p-values p<0.05; results in Table 3 and Fig 4).
Discussion
Liver fibrosis, as measured by a high APRI or FIB-4 score, was associated with an increase in a
number of inflammatory mediators including sICAM, sVCAM and IP-10 in women with
chronic hepatitis C (HCV RNA+) compared to HCV RNA- women. One chemokine in partic-
ular, IP-10, an interferon-induced protein that has been implicated in liver fibrosis [34,35] and
lower ability to clear infection [36], was elevated in HCV RNA+ women even among those
women with suppressed HIV replication (elite controllers and ART responders). The very
high IP-10 levels seen in the women with uncontrolled HIV replication dominate the relatively
weaker IP-10 induction driven by HCV RNA. Other studies have shown increased hepatic dis-
ease and greater liver-related mortality in HIV-infected individuals with HCV co-infection
[37,38], and our study identifies several pro-inflammatory markers potentially mechanistic
associated with increased liver pathology. While ART control and/or elite control was associ-
ated with reduced IP-10, the inflammatory effects of HIV infection persisted when compared
to HIV uninfected women [7].
The mechanisms underlying increased hepatic injury during HIV/HCV co-infection are
not well understood. Strong anti-HCV cellular and antibody responses are induced during
acute infection, and while in some cases this may result in resolved infection, in other cases the
HCV infection persists [39,40]. There is evidence that cytokine and chemokine production,
increased cell adhesion molecule expression, and cellular infiltration to the sites of hepatic
infection contribute to tissue damage and fibrosis in HIV/HCV co-infected subjects [23]. A
decrease in IFN-γ producing T cells show a reduction in anti-viral immune responses in the
liver and reduced concentrations of regulatory T cells and elevated levels of chemokines and
monocytes trafficking to the liver may promote liver fibrosis [41–43]. Previous studies have
shown elevations in sVCAM-1 and sICAM-1 in advanced fibrosis and as predictors of liver-
related events [44,45]. Our current work would support this hypothesis, showing the markers
Table 2. (Continued)
HIV negative Elite RNA Neg ART Controlled ART Uncontrolled
HCV RNA Neg HCV RNA Pos HCV RNA Neg HCV RNA Pos HCV RNA Neg HCV RNA Pos HCV RNA Neg HCV RNA Pos
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Fig 1. Cytokines and chemokines correlate with liver fibrosis. Cytokines, chemokines and cell adhesion
molecules were evaluated for correlation with APRI, a marker of liver fibrosis. The subgroups were broken down by
color: HIV Neg (blue), Elite (green), HIV uncontrolled (ARTuc; red) and HIV controlled (ARTc; orange), and by HCV
RNA status: positive (closed circles) and negative (open circles).
https://doi.org/10.1371/journal.pone.0181004.g001
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Fig 2. VCAM-1, ICAM-1 and IP-10 as soluble markers of HCV replication. Cytokines, chemokines and cell adhesion molecules were compared
across HCV RNA status. The bars represent the median and interquartile ranges.
https://doi.org/10.1371/journal.pone.0181004.g002
Fig 3. Elevations in IP-10 in HIV-HCV co-infection. Significant elevations of IP-10 were observed in all HCV RNA+ groups compared to HCVRNA-
except for ARTuc. The bars represent the median and interquartile ranges.
https://doi.org/10.1371/journal.pone.0181004.g003
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associated with fibrosis in this study were pro-inflammatory chemokines (IP-10), cytokines
(IL-10) or were soluble cell adhesion molecules (sVCAM-1, sICAM-1). In line with this ele-
vated inflammation with uncontrolled HIV replication we found significantly higher levels of
TNF- α, IP-10 and GRO.
Table 3. HCV RNA+ cytokine comparison in HIV negative and HIV positive groups.





MPO 0.04 (0.54) 0.006 (0.07) 0.03 (0.26)
FGF-2 0.015 (0.36) 0.013 (0.12)
GRO 0.03 (0.26)
IL-17 0.04 (0.21)
IP-10 0.0006 (0.1) 0.007 (0.26) 0.04 (1)
MCP-1 0.005 (0.27) 0.005 (0.23)
MDC 0.03 (0.77) 0.02 (0.42) 0.02 (0.26)
TGF-α 0.003 (0.16) 0.02 (0.13)
https://doi.org/10.1371/journal.pone.0181004.t003
Fig 4. Differential expression of soluble immune mediators in HCV RNA+ individuals. The HCV RNA+ HIV negative and HIV positive groups
were compared for all cytokines measured. Groups with significant cytokine differences are identified as p<0.05; a false discovery rate adjustment for
multiple comparisons was performed (Benjamini Hochberg) all values are presented.
https://doi.org/10.1371/journal.pone.0181004.g004
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A few factors were found to be negatively correlated with APRI including IL-17, EGF, TGF-
α and MMP-9 levels. Expression of these factors may result in a protective effect and reduced
hepatic injury. Although many reports on the mechanisms of fibrosis indicate a link between
pro-inflammatory mediators, such as IL-17, and hepatic injury and fibrosis, we found an
inverse correlation between IL-17 and APRI score (r = -0.25; p = 0.02) with no relationship
between IL-17 and CD4 count (r = 0.11, p = 0.3). Studies have shown that IL-17 exacerbates
hepatic fibrosis in mice; however, co-expression of IL-17 and IL-22 has also been shown to
ameliorate fibrosis [46]. This is further supported by the finding in another murine study that
IL-22 induces senescence in hepatic stellate cells, thereby reducing fibrosis [47], which remains
to be investigated since IL-22 was not assessed in our study. We found that EGF, MMP-9 and
TGF- α levels were inversely correlated with APRI; in the HIVuc group, we also found signifi-
cantly lower levels of FGF-2, MMP-9 and MPO compared to the other groups. EGF and TGF-
α have a role in the regenerative response in the liver and EGF family members have been
shown to inhibit TGF-β induced hepatic stellate cell activation and fibrosis induction [48–50].
Interestingly, TGF-α induces expression of MMPs which are involved in fibrinolysis [51]. In a
murine model, after Flt3L-expressing B16 melanoma cells were injected into mice, it induced
dendritic cell expression of MMP-9, which in turn reduced fibrosis [52]. Further studies inves-
tigating the expression of these markers on would be important in elucidating the mechanisms
of protection from fibrosis.
After comparing the cytokines by HIV positive and negative groups, two different profiles
of responses become evident. There is a subset of cytokines that shows higher concentrations
in the ART-treated HCV+ groups (TNF-α, GRO, IP-10 and MDC) and a subset that shows
lower concentrations in ART-treated groups (MCP-1, MDC, FGF-2, MPO, sE-Selectin, MMP-
9, IL-17, GM-CSF and TGFα); although some differences were seen in both ART-treated
groups, the differences were most evident in the group with uncontrolled HIV. As seen by ear-
lier analysis, IP-10 in the HCV+ ART-treated groups was also found to be significantly corre-
lated with increased fibrosis. Similarly, IL-17, TGF-α and MMP-9 were higher in the HIV
negative and Elite groups and correlated with lower fibrosis. A number of the p-values were
higher after correcting for false discovery rate and this may be due to the small sample size of
the study groups. Regardless, the discovery of these markers is important in understanding the
mechanism of pathogenesis in HIV and HCV co-infection and validation of these markers in
larger, more targeted studies of these biomarkers will be required.
There are certain limitations to our study. Given the stringent eligibility criteria for inclu-
sion in these analyses, sample size was limited by the number of available elite controllers;
other groups were selected to achieve similar age and race distributions. Although small, our
HIV groups were carefully selected and represented extremes of control or lack of control of
HIV infection. These extreme HIV groups have not been studied in HCV viremic and non
viremic women and show that both HIV and HCV status are important in immune responses.
Our marker of fibrosis, APRI, was calculated from available clinical information was used as a
surrogate for liver fibrosis and was highly correlated with the alternative marker for fibrosis,
FIB-4. Both of these markers have been validated in WIHS and other studies and shown to be
independently associated with all-cause mortality in HCV/HIV phenotypic groups (elite, ART
controlled, ART uncontrolled, and HIV negative). Spearman correlation coefficients were 0.83
(p = 0.002), 0.83 (p = 0.003), 0.99 (p<0.001), and 0.89 (p<0.001), respectively [30,53–55]. We
found similar results in the analysis of fibrosis and soluble markers (Fig 1 and S1 Fig). There-
fore, we proceeded with APRI throughout the analysis of coinfected women. In summary, we
have identified a panel of biomarkers that are associated with unresolved HCV infection with
and without HIV co-infection. In the HCV RNA+ group, APRI scores, sICAM, sVCAM, and
IP-10 all were elevated, pointing to a potential pathway whereby HCV replication drives
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inflammation and induces hepatic fibrosis. APRI in HCV RNA+ positively correlated with
markers of inflammation and higher concentrations of these markers were especially seen in
ART-treated subjects with uncontrolled HIV replication implying that co-infection can
amplify the pro-inflammatory effects of HCV replication. Finally, a subset of markers was
found associated with lower fibrosis and with HIV negative or viremic control and these mark-
ers may be important in identifying a better prognosis in Elite or treated individuals. Our find-
ings will inform future investigations into the underlying mechanisms of liver pathogenesis
and will reveal inflammatory mediators most relevant to these processes. The clinical implica-
tion of these findings is that new, potent anti-HCV therapy may be more effective in reducing
the pro-inflammatory environment in those HIV co-infected subjects who have controlled
HIV replication, and likely would not significantly reverse the inflammatory state in those
with uncontrolled HIV replication. However, anti-HCV therapy would be predicted to halt or
slow liver fibrosis, even among subjects with uncontrolled HIV replication.
Supporting information
S1 Fig. Cytokines and chemokines correlate with liver fibrosis. Cytokines, chemokines and
cell adhesion molecules were evaluated for correlation with FIB-4, a marker of liver fibrosis.
The subgroups were broken down by color: HIV Neg (blue), Elite (green), HIV uncontrolled
(ARTuc; red) and HIV controlled (ARTc; orange), and by HCV RNA status: positive (closed
circles) and negative (open circles).
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